Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients.
The addition of target therapy to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a review / Benevento, Ilaria; DE FELICE, Francesca; Musio, Daniela; Tombolini, Vincenzo. - In: CHEMOTHERAPY. - ISSN 0009-3157. - STAMPA. - 62:5(2017), pp. 314-322. [10.1159/000476056]
The addition of target therapy to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a review
BENEVENTO, ILARIACo-primo
;DE FELICE, FRANCESCA
Co-primo
;TOMBOLINI, VincenzoUltimo
2017
Abstract
Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients.File | Dimensione | Formato | |
---|---|---|---|
Benevento_Addition_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
4.46 MB
Formato
Adobe PDF
|
4.46 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.